Dr. Folefac Aminkeng is an Assistant Principal Investigator and the Associate Head of the Pharmacogenomics and Personalized Medicine Program at the Agency for Science Technology and Research (A*STAR) in Singapore. His central research interests are on the "Pharrmacogenomics of Adverse Drug Reactions in Oncology", with a particular focus on Cardiotoxicity, Ototoxicity, Nephrotoxicity and Neurotoxicity. He is interested in bio-marker discovery, validation, translation and guidelines development, as well the implementation of pharmacogenomic testing to provide real time decision support to improve the safety of cancer treatments. Folefac obtained his master's degree and PhD in Medical Sciences from the Vrije Universiteit Brussel in Belgium and did his postdoctoral training on pharmacogenomics and precision medicine at the Centre for Molecular Medicine and Therapeutics of the British Columbia Children Hospital Research Institute and the Department of Medical Genetics of the University of British Columbia. He has made significant contributions to the field of pharmacogenomics including the identification of a gene that is involved in cardiomyopathy and congestive heart failure after cancer treatment (Aminkeng F et al, Nature Genetics. 2015 Sep; 47(9):1079-84.). He is the recipient of a number of fellowships including the Canadian Institutes of Health Research, Michael Smith Foundation for Health Research and the British Columbia Children Hospital Research Institute Bertram Hoffmeister Postdoctoral Fellowships. He has also been recognized for a distinguish academic and scientific career through a number of career awards including the Canadian Society of Pharmacology and Therapeutics Boehringer Ingelheim Postdoctoral Award in Pharmacology, the British Columbia Children Hospital Research Institute award for outstanding achievement by a postdoctoral fellow, the Golden Helix Top Prize and the Canadian Society of Pharmacology and Therapeutics Publication Award. He currently serves on the Editorial Board of the Journal of Population Therapeutics and Clinical Pharmacology and is a member of the Canadian Society of Pharmacology and Therapeutics Scientific Program Committee.